Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,346,938 papers from all fields of science
Search
Sign In
Create Free Account
herpesvirus protein gp57-65
Known as:
HVT gp57-65 protein, Herpesvirus
, gp 57-65 protein, Herpesvirus
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Glycoproteins
Viral Proteins
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Evaluation of the Protection against Infectious Bursal Disease (IBD) Challenge in Progeny Born to Parents Having Received a Vaccination Program Using a Herpesvirus of Turkey-Infectious Bursal Disease…
S. Lemiere
,
Jean-Claude Gauthier
,
A. Kodjo
,
Laure Vinit
,
A. Delvecchio
,
F. Prandini
2013
Corpus ID: 35036853
Broiler breeder vaccination against IBD is usually based on the injection of at least one inactivated vaccine in oil adjuvant…
Expand
2009
2009
IBD efficacy data in presence of maternal antibodies in broilers and layers with a novel vector HVT-IBD vaccine.
F. Gros
,
U. Heffels-Redmann
,
D. Sommer
,
E. Kaleta
2009
Corpus ID: 83222313
2008
2008
EVALUATION OF A HERPESVIRUS OF TURKEY VECTOR VACCINE INDUCING PROTECTION AGAINST INFECTIOUS BURSAL AND MAREKS DISEASES (VAXXITEK® HVT + IBD) UNDER PHILIPPINES FIELD CONDITIONS
J. Atienza
,
A. J. Nagera
,
+4 authors
S. Lemiere
2008
Corpus ID: 52265876
A field study was conducted to evaluate the safety and efficacy of a Herpesvirus of Turkey (HVT) vector vaccine inducing…
Expand
1987
1987
Biological characteristics of Marek's disease vaccine CVI-988 clone C1.
G. F. de Boer
,
J. M. A. Pol
,
H.L. Oei
Veterinary Quarterly
1987
Corpus ID: 31012498
Biological characteristics of Marek's disease virus (MDV) CVI-988 clone C, of importance for vaccine application, are described…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE